Research Article
Glutathione as a Biomarker in Parkinson’s Disease: Associations with Aging and Disease Severity
Table 1
Participant demographics.
| | | CNS uptake
Mean (SD) | Phase IIb
Mean (SD) | Combined
Mean (SD) |
| | Gender | | | | | Male | 11 (73%) | 22 (51%) | 33 (57%) | | Female | 4 (27%) | 21 (49%) | 25 (43%) | | Age, years | 65.5 (11.2) | 62.2 (10.8) | 62.2 (10.8) | | Disease severity | | | | | Years since PD diagnosis | 6.15 (6.24) | 3.54 (2.2) | 4.26 (3.9) | | UPDRS | 78.9 (15.4) | 67.8 (9.5) | 70.7 (12.2) | | PRO-PD | 869 (334) | 804 (422) | 821 (399) | | Hoehn & Yahr | | | | | 1 | | 9 (20.9%) | 9 (15.5%) | | 1.5 | | 6 (14.0%) | 6 (10.3%) | | 2 | 6 (40%) | 17 (39.5%) | 23 (39.7%) | | 2.5 | 4 (27%) | 7 (16.3%) | 11 (19.0%) | | 3 | 5 (33%) | 4 (9.3%) | 9 (15.5%) |
|
|
UPDRS: Unified Parkinson’s Disease Rating Scale; PRO-PD: Patient-Reported Outcomes in Parkinson’s Disease.
|
